Continuous Glucose Monitoring Use in Clinical Trials for On-Market Diabetes Drugs
figureposted on 22.01.2021, 20:54 by Bradley Q. Fox, Peninah F. Benjamin, Ammara Aqeel, Emily Fitts, Spencer Flynn, Brian Levine, Elizaveta Maslak, Rebecca L. Milner, Benjamin Ose, Michael Poeschla, Meghna Ray, Maeve Serino, Sahaj S. Shah, Kelly L. Close
Despite the growing momentum behind a movement to augment adoption of continuous glucose monitoring (CGM) in clinical practice and investigation, to the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacologic agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 diabetes therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov listings, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from <5% before 2005 to 12.5% in 2019. However, it is still low given its inclusion in the American Diabetes’s Association’s latest guidelines and known limitations of A1C for assessing ongoing diabetes care.